Alector Management
Management criteria checks 2/4
Alector's CEO is Arnon Rosenthal, appointed in Jan 2013, has a tenure of 11.42 years. total yearly compensation is $4.26M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 5.72% of the company’s shares, worth $23.84M. The average tenure of the management team and the board of directors is 2.4 years and 5.3 years respectively.
Key information
Arnon Rosenthal
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 15.4% |
| CEO tenure | 11.4yrs |
| CEO ownership | 5.7% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%
Jan 19Alector: Good Data, Huge Cash, No Near Term Catalyst
Jan 16Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Sep 25Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Jun 27Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week
Mar 02Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
Jan 16Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
Oct 04AbbVie ends partnership with Alector for Alzheimer’s candidate
Jul 08Alector: Potential In Neurology And Cancer Treatments
Jun 14Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022
May 18Alector: Expect Phase 3 Data Next Year
Apr 16These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts
Feb 27Alector, Inc: A Newer Biotech Company With Big Potential
Jan 26Alector: The GSK Deal Is A Major Value Add
Oct 29We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate
Sep 27This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year
Aug 05New Forecasts: Here's What Analysts Think The Future Holds For Alector, Inc. (NASDAQ:ALEC)
Jul 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$121m |
| Dec 31 2023 | US$4m | US$654k | -US$130m |
| Sep 30 2023 | n/a | n/a | -US$141m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$4m | US$621k | -US$133m |
| Sep 30 2022 | n/a | n/a | -US$136m |
| Jun 30 2022 | n/a | n/a | US$36m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$10m | US$575k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$212m |
| Mar 31 2021 | n/a | n/a | -US$202m |
| Dec 31 2020 | US$4m | US$554k | -US$190m |
| Sep 30 2020 | n/a | n/a | -US$169m |
| Jun 30 2020 | n/a | n/a | -US$148m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$7m | US$525k | -US$105m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$76m |
| Mar 31 2019 | n/a | n/a | -US$62m |
| Dec 31 2018 | US$5m | US$397k | -US$52m |
| Sep 30 2018 | n/a | n/a | -US$45m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$35m |
| Dec 31 2017 | US$3m | US$370k | -US$32m |
Compensation vs Market: Arnon's total compensation ($USD4.26M) is above average for companies of similar size in the US market ($USD2.49M).
Compensation vs Earnings: Arnon's compensation has increased whilst the company is unprofitable.
CEO
Arnon Rosenthal (68 yo)
11.4yrs
Tenure
US$4,255,007
Compensation
Dr. Arnon Rosenthal, Ph D., Co-Founded Annexon in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Ale...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$4.26m | 5.72% $ 23.8m | |
| President and Head of Research & Development | 2.5yrs | US$2.61m | 0.13% $ 553.0k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 2.3yrs | US$1.72m | 0.029% $ 120.7k | |
| Chief Medical Officer | 2.1yrs | US$1.62m | 0.069% $ 287.3k | |
| Chief Scientific Officer | 2.4yrs | no data | no data | |
| Senior Director of Corporate Communication & Investor Relations | no data | no data | no data | |
| General Counsel | 2.4yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Regulatory | no data | no data | no data | |
| Chief of Staff & Head of Strategy | 2.4yrs | no data | no data | |
| Senior Vice President of Portfolio & Program Management | 2.4yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
2.4yrs
Average Tenure
56yo
Average Age
Experienced Management: ALEC's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$4.26m | 5.72% $ 23.8m | |
| Independent Chairperson of the Board | 5.7yrs | US$355.07k | 0.037% $ 154.3k | |
| Director & Member of Scientific Advisory Board | 5.7yrs | US$509.13k | 0.046% $ 191.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.7yrs | US$324.71k | 0.083% $ 347.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$318.92k | 0.037% $ 154.3k | |
| Independent Director | 4.8yrs | US$318.12k | 0.039% $ 162.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Independent Director | 2.8yrs | US$322.27k | 0.027% $ 113.4k |
5.3yrs
Average Tenure
67yo
Average Age
Experienced Board: ALEC's board of directors are considered experienced (5.3 years average tenure).